ResMed Boasts Double-Digit EPS Growth, Tariff Exemption: Analysts Boost Price Forecast

On Wednesday, ResMed Inc RMD reported that third-quarter adjusted EPS was $2.37, beating the consensus of$2.36.Quarterly sales increased 8% year over year to $1.29 billion, which aligns with estimates.Sales increased 9% on a constant currency basis. The company credited increased demand for sleep devices and growth within the Residential Care Software business. In addition:Revenue in the U.S., Canada, and Latin America, excluding Residential Care Software, grew by 9%.Revenue in Europe, Asia, and other mark ...